Deals and Financings
- Berry Genomics, a Beijing diagnostics/sequencing company, completed a $648 million reverse merger on the Shenzhen exchange;
- China’s iPharma agreed in principle to a $120 million deal for Greater China rights to a clinical-stage immunotherapy candidate from Mologen of Berlin;
- Suzhou’s CF PharmaTech raised $65 million in a Series D funding to advance its inhalation products;
- aTyr Pharma, a public San Diego-Hong Kong biotherapeutics company, announced a $45.8 million private placement;
- Akeso Biopharma of Zhongshan closed a $45 million B round, led by the GTJA Investment Group, to develop its antibody portfolio;
- Fosun Pharma paid $40 million to acquire a 65% stake in Shanghai SinoMedCare Biotech, a medical marketing company focused on tier 3 China cities;
- Distinct Healthcare of China closed a $40 million C funding round to support its chain of China medical clinics;
- Shuidi, a China crowdfunding platform aimed at helping people pay for healthcare, raised $24 million in a Series A round led by Tencent Holdings;
Company News
- Beijing’s Yisheng Biopharma said its first-in-class immuno-oncology candidate, YS-ON-001, showed “breakthrough” anti-tumor efficacy in pre-clinical tests;
Trials and Approvals
- iCAD, a New Hampshire medical device maker, announced CFDA approval of its balloon applicators, which are used in Brachytherapy treatment of breast cancer.
